Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 2:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 118 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: dilation and curettage Clear all
Terminated Phase 1 Interventional

Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma

NCT02116959
View directory record Official record
Conditions
Advanced Intra-Ocular Retinoblastoma, Retinoblastoma
Interventions
Melphalan, Carboplatin, Etoposide, Vincristine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Months to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Sep 18, 2026, 2:58 AM EDT
Completed Phase 2Phase 3 Interventional

Mindfulness Meditation in Bone Marrow Transplantation

NCT00165282
View directory record Official record
Conditions
Hematologic Malignancy, Bone Marrow Transplantation, Stem Cell Transplantation
Interventions
Mindfulness training, Nurse education
Behavioral
Lead sponsor
Emory University
Other
Eligibility
21 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Sep 18, 2026, 2:58 AM EDT
Completed Phase 1 Interventional

A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection

NCT03980314
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Hartford, Connecticut • Minneapolis, Minnesota • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 18, 2026, 2:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TA-65 Pharmacokinetic Study

NCT02731807
View directory record Official record
Conditions
Healthy
Interventions
Dose A: TA-65 24mg, powder, Dose B: TA-65, 8mg, powder, Dose C: TA-65 3.2mg, capsule, Dose D: TA-65 8mg, capsule, Dose E: TA-65 32mg, capsule
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
22 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 18, 2026, 2:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses

NCT00360737
View directory record Official record
Conditions
Healthy
Interventions
Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 18, 2026, 2:58 AM EDT
Withdrawn Not applicable Interventional

Optical Coherence Tomography Guided C&D

NCT04510727
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Optical Coherence Tomography (OCT), Curettage & Desiccation (C&D) Procedure
Device · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 18, 2026, 2:58 AM EDT
Active, not recruiting Phase 1 Interventional

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

NCT05245006
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
89Zr-DFO-YS5, YS5 antibody, Positron Emission Tomography (PET)/Computerized tomography (CT), Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
Drug · Biological · Procedure
Lead sponsor
Robert Flavell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 18, 2026, 2:58 AM EDT
Completed Phase 1 Interventional

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

NCT02231723
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
BBI608, Nab-paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, Fluorouracil, MM-398
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
12
States / cities
Phoenix, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 18, 2026, 2:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Climate Labels for Restaurant Menus Pilot

NCT06651060
View directory record Official record
Conditions
Food Selection
Interventions
Menu label
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
16,181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 18, 2026, 2:58 AM EDT
Recruiting Not applicable Interventional

Hysteroscopic Resection Versus Manual Vacuum Aspiration for Early Pregnancy

NCT07088510
View directory record Official record
Conditions
Miscarriage in First Trimester
Interventions
Hysteroscopic resection, Manual Vacuum Aspiration
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 18, 2026, 2:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Combination Study With MVA BN and Dryvax

NCT00082446
View directory record Official record
Conditions
Smallpox
Interventions
Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 32 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Sep 18, 2026, 2:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MENU Study: Online Experiment

NCT06909019
View directory record Official record
Conditions
Food Selection
Interventions
Control (QR) Labels, Low Climate Impact Labels, High Climate Impact Labels, Traffic Light Labels, Climate Grade Labels
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
6,294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 18, 2026, 2:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Botox and Suction-Curettage for Treatment of Excessive Underarm Sweating (Axillary Hyperhidrosis)

NCT01274611
View directory record Official record
Conditions
Axillary Hyperhidrosis
Interventions
Botulinum Toxin Type A, Suction-Curettage
Drug · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Sep 18, 2026, 2:58 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Same-day Dilapan-S With Adjunctive Misoprostol

NCT01818414
View directory record Official record
Conditions
Therapeutic Abortion
Interventions
Misoprostol, Folic Acid
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 18, 2026, 2:58 AM EDT
Not listed Not applicable Interventional

Prospective Study of Adjunctive Carotenoids Plus Anti-oxidants in Anti-VEGF Treated Diabetic Macular Edema

NCT03866005
View directory record Official record
Conditions
Center-involved Diabetic Macular Edema (CI-DME)
Interventions
Diabetes Visual Function Study (DiVFuSS) softgels, canola oil placebo softgels, 2 per day
Dietary Supplement · Other
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Olympia, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Sep 18, 2026, 2:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants

NCT03127189
View directory record Official record
Conditions
Healthy
Interventions
Rilpivirine, Rilpivirine Long-acting Parenteral Formulation
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 18, 2026, 2:58 AM EDT
Completed Phase 2 Interventional Results available

Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab

NCT04401995
View directory record Official record
Conditions
Melanoma
Interventions
Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
Drug · Biological · Other
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 18, 2026, 2:58 AM EDT
Completed Phase 2 Interventional

Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320

NCT00000885
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
52
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 18, 2026, 2:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

NCT02277600
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Darunavir, Cobicistat
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 18, 2026, 2:58 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

NCT07193550
View directory record Official record
Conditions
Bone Sarcomas
Interventions
Zanzalintinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 18, 2026, 2:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

NCT03978143
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 18, 2026, 2:58 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

NCT02955290
View directory record Official record
Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, PD-L1 Positive, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Advanced Squamous Non-Small Cell Lung Carcinoma
Interventions
Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Other · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Indianapolis, Indiana • Buffalo, New York • Roslyn, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 18, 2026, 2:58 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

RCT for Women With a Persisting Pregnancy of Unknown Location

NCT01800162
View directory record Official record
Conditions
Persistent Pregnancy of Unknown Location, Ectopic Pregnancy
Interventions
Methotrexate, Uterine Evacuation, Expectant Management
Drug · Procedure · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Sep 18, 2026, 2:58 AM EDT
Completed Not applicable Interventional

Individualized Piano Instruction (IPI) for Improving Cognition in Breast Cancer Survivors.

NCT05909813
View directory record Official record
Conditions
Breast Cancer, Chemotherapy-Related Cognitive Impairment
Interventions
Individualized Piano Keyboard Instruction
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 18, 2026, 2:58 AM EDT